story of the week
Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL and SLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
J. Clin. Oncol 2022 Nov 17;[EPub Ahead of Print], P Hillmen, B Eichhorst, JR Brown, N Lamanna, SM O'Brien, CS Tam, L Qiu, M Kazmierczak, K Zhou, M Šimkovič, J Mayer, A Gillespie-Twardy, M Shadman, A Ferrajoli, PS Ganly, R Weinkove, S Grosicki, A Mital, T Robak, A Österborg, HA Yimer, T Salmi, M Ji, J Yecies, A Idoine, K Wu, J Huang, W JurczakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.